Research Use Only. Peptides Lab UK supplies research-grade materials for in-vitro laboratory research only. Nothing on this page is medical advice or an instruction for human or animal use, and no product sold on this website is a medicine.
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), stabilised by an N-terminal trans-3-hexenoyl group. It has been authorised in some countries for a specific indication (excess abdominal fat in HIV-associated lipodystrophy); it is not an authorised medicine in the UK.
Published research
A randomised, placebo-controlled trial in HIV-infected patients with abdominal fat accumulation reported reductions in visceral adipose tissue with tesamorelin, and reviews summarise its development and safety profile in that population. These findings relate to a defined patient population under medical supervision and do not support general claims.[1,2,3]
Limitations of the evidence
Much of the available literature is preclinical (cell and animal models) or comes from small numbers of research groups. Findings in defined experimental systems cannot be extrapolated to other settings, and this page does not provide dosing, administration or human-use information.
Laboratory handling and storage
Lyophilised peptides are generally stored sealed, protected from light and moisture, at low temperature as specified on the certificate of analysis. Once reconstituted for in-vitro work, solutions are typically kept refrigerated and used within a validated stability window. Researchers should follow their institution’s procedures and the batch documentation (HPLC purity and mass-spectrometry identity) supplied with each lot.
UK regulatory status
In the UK, medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Research-grade compounds sold by Peptides Lab UK are supplied strictly for laboratory research; they are not medicinal products, are not manufactured to medicinal GMP standards and must not be used in humans or animals.
Related research pages
References
- Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010; 53(3):311-22. doi:10.1097/QAI.0b013e3181cbdaff PMID: 20101189.
- Dhillon S et al. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011; 71(8):1071-91. doi:10.2165/11202240-000000000-00000 PMID: 21668043.
- Spooner LM et al. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012; 46(2):240-7. doi:10.1345/aph.1Q629 PMID: 22298602.
Disclaimer: All products sold by Peptides Lab UK are for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.
